select a format

Single User License
USD 250 INR 16035
Site License
USD 500 INR 32070
Corporate User License
USD 750 INR 48105

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Orion Oyj (ORNBV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Orion Oyj (ORNBV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH32020D
  • |
  • Pages: 76
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Orion Oyj (Orion) develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. It focuses on developing pharmaceutical products for central nervous system disorders, cancer and respiratory. Its client base consists of healthcare service providers and professionals, such as doctors, pharmacies, hospitals, healthcare centers, clinics and laboratories. It operates two businesses, namely, Pharmaceuticals and Diagnostics. Major brands of the company include Antisedan, Comtess, Comtan, Dexdomitor, Domitor, Domosedan, Stalevo, SimdaxEasyhale and Precedex among others. It operates all manufacturing plants and most of its R&D facilities in Finland and markets its products in over 100 countries. Orion is headquartered in Espoo, Finland.

Orion Oyj (ORNBV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Orion Oyj, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Orion Oyj, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Orion Oyj, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Orion Oyj, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Orion Oyj, Medical Devices Deals, 2011 to YTD 2017 10

Orion Oyj, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Orion Oyj, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Orion to Partner with Wisconsin Technology Innovation Initiative 13

Immunscape Enters into Research Collaboration with Orion 13

Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 14

Orion Enters into Agreement with Asahi Kasei Pharma 15

Orion Enters into Co-Development Agreement with Helsinki University 15

Vetoquinol Enters into Distribution Agreement with Orion Pharma 16

Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 17

Orion Enters Into R&D Agreement With Gedeon Richter For Cognitive Disorders 18

Nycomed Enters Into Co-Marketing Agreement With Orion For Easyhaler 19

Eisai Enters Into Co-Marketing Agreement With Orion For Fareston And Eldepryl 20

Endo Pharma Enters Into Research Collaboration With Orion 21

Licensing Agreements 22

A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 22

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 22

Orion Enters Into Licensing Agreement With Janssen Pharma 23

Orion And Hospira Extend Licensing Agreement For Precedex 24

Mylan Enters Into Licensing Agreement With Orion for Stalevo 25

Orion Enters Into Licensing Agreement With ProStrakan For Fareston 26

Nycomed Enters Into Licensing Agreement With Orion For Easyhaler 27

Debt Offering 29

Orion Announces Public Offering Of Bond Due 2019 For US$193 Million 29

Orion Oyj-Key Competitors 30

Key Employees 31

Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 34

Financial Announcements 34

Apr 26, 2017: Orion Group Interim Report January-March 2017 34

Feb 08, 2017: Orion Group Financial Statement Release for 2016 35

Oct 25, 2016: Orion Group Interim Report January-September 2016 38

Jul 19, 2016: Orion Group Half-Yearly Report January-June 2016 39

Jun 15, 2016: Orion upgrades full-year outlook for 2016 45

Apr 27, 2016: Orion Group Interim Report January-March 2016 46

Feb 02, 2016: Orion Group Financial Statement Release for 2015 55

Corporate Communications 66

Feb 13, 2017: Change in Orion Group Executive Management Board as of 21 February 2017 66

Jan 27, 2017: Reijo Salonen, Senior Vice President, Pharmaceutical R&D, is CTO of the Year 2017 67

Government and Public Interest 68

Feb 10, 2017: Orion Research Foundation grants EUR 1 million for research 68

Product News 69

05/19/2016: Bayer to Showcase Latest Data on ODM-201 at ASCO 2016 69

Product Approvals 70

Dec 21, 2016: Orion is planning to apply for a marketing authorisation for combined salmeterol-fluticasone formulation of the Easyhaler product family 70

Clinical Trials 71

Nov 18, 2016: Tenax Therapeutics Announces Completion of Enrollment for Phase 3 LEVO-CTS Trial in Cardiac Surgery 71

Oct 05, 2016: Tenax Therapeutics Provides Clinical Updates for Lead Candidate Levosimendan 72

Jun 03, 2016: Bayer and Orion Expand Clinical Development Program With New Phase III Study ARASENS for BAY-1841788 (ODM-201) in Prostate Cancer 73

Feb 01, 2016: Tenax Therapeutics Provides Update of Phase 3 LEVO-CTS Trial for LCOS 74

Other Significant Developments 75

Mar 11, 2016: Fermion invests in a new production facility in Hanko 75

Appendix 76

Methodology 76

About GlobalData 76

Contact Us 76

Disclaimer 76

List of Figures

Orion Oyj, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Orion Oyj, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Orion Oyj, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Orion Oyj, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Orion Oyj, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Orion Oyj, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Orion Oyj, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Orion Oyj, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Orion Oyj, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Orion Oyj, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Orion Oyj, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Orion Oyj, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Orion Oyj, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Orion Oyj, Deals By Therapy Area, 2011 to YTD 2017 9

Orion Oyj, Medical Devices Deals, 2011 to YTD 2017 10

Orion Oyj, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Orion to Partner with Wisconsin Technology Innovation Initiative 13

Immunscape Enters into Research Collaboration with Orion 13

Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 14

Orion Enters into Agreement with Asahi Kasei Pharma 15

Orion Enters into Co-Development Agreement with Helsinki University 15

Vetoquinol Enters into Distribution Agreement with Orion Pharma 16

Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 17

Orion Enters Into R&D Agreement With Gedeon Richter For Cognitive Disorders 18

Nycomed Enters Into Co-Marketing Agreement With Orion For Easyhaler 19

Eisai Enters Into Co-Marketing Agreement With Orion For Fareston And Eldepryl 20

Endo Pharma Enters Into Research Collaboration With Orion 21

A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 22

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 22

Orion Enters Into Licensing Agreement With Janssen Pharma 23

Orion And Hospira Extend Licensing Agreement For Precedex 24

Mylan Enters Into Licensing Agreement With Orion for Stalevo 25

Orion Enters Into Licensing Agreement With ProStrakan For Fareston 26

Nycomed Enters Into Licensing Agreement With Orion For Easyhaler 27

Orion Announces Public Offering Of Bond Due 2019 For US$193 Million 29

Orion Oyj, Key Competitors 30

Orion Oyj, Key Employees 31

Orion Oyj, Subsidiaries 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Orion Oyj, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com